Medpace Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Medpace Holdings şirketinin toplam hissedar öz sermayesi $881.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $2.1B ve $1.2B dir. Medpace Holdings 'in FAVÖK'ü $408.8M faiz karşılama oranı -21.6 dur. Şirketin $656.9M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-21.6x
Nakit	US$656.90m
Eşitlik	US$881.44m
Toplam yükümlülükler	US$1.20b
Toplam varlıklar	US$2.08b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MEDP * 'nin kısa vadeli varlıkları ( $1.0B ) kısa vadeli yükümlülüklerini ( $1.0B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: MEDP * şirketinin kısa vadeli varlıkları ( $1.0B ) uzun vadeli yükümlülüklerini ( $161.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MEDP * borçsuzdur.

Borcun Azaltılması: MEDP * un 5 yıl önce borcu yoktu.

Borç Kapsamı: MEDP * un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: MEDP * şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Medpace Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Medpace Holdings, Inc. to Report Q3, 2024 Results on Oct 21, 2024

Second quarter 2024 earnings released: EPS: US$2.85 (vs US$2.00 in 2Q 2023)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024

First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Insufficient new directors

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024

Insufficient new directors

Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024

Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive Index

Insufficient new directors

First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022)

Insufficient new directors

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023

Insufficient new directors

Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board

Insufficient new directors

Insufficient new directors

CFO & Treasurer recently sold Mex$8.8m worth of stock

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021)

Medpace Holdings, Inc. (NasdaqGS:MEDP) announces an Equity Buyback for $500 million worth of its shares.

Insufficient new directors

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2022 and 2023

Medpace Holdings, Inc. to Report Q3, 2022 Results on Oct 24, 2022

Chairman & CEO recently bought Mex$292m worth of stock

Insufficient new directors

Chairman & CEO recently bought Mex$207m worth of stock

Investor sentiment deteriorated over the past week

Insufficient new directors

Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Insufficient new directors

Medpace Holdings, Inc. to Report Q2, 2022 Results on Jul 25, 2022

Insufficient new directors

Insufficient new directors

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc., Annual General Meeting, May 20, 2022

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$1.5m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medpace Holdings, Inc. Provides Consolidated Earnings Guidance for the Year 2022

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021

Executive Vice President of Operations recently sold Mex$22m worth of stock

Medpace Holdings, Inc. to Report Q1, 2021 Results on Apr 26, 2021

Executive Vice President of Operations recently sold Mex$22m worth of stock

Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019)

Revenue beats expectations

Investor sentiment improved over the past week

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index

Medpace Holdings, Inc. to Report Q4, 2020 Results on Feb 15, 2021

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from S&P 600 Health Care (Sector)

Medpace Holdings, Inc. to Report Q3, 2020 Results on Oct 26, 2020

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin